🍽️ ketanserin tartrate hydrate,(prescription)

AI Engines For more Details: PerplexityKagi LabsYou

  1. Antihypertensive Action: Ketanserin tartrate hydrate is a selective antagonist of serotonin (5-HT2) receptors. By blocking these receptors, it causes vasodilation (widening of blood vessels), leading to a decrease in blood pressure. It is particularly effective in treating hypertension (high blood pressure), especially in patients with elevated levels of circulating serotonin.

  2. Vascular Conditions: Ketanserin tartrate hydrate is used to manage various vascular conditions, including peripheral vascular disease (PVD) and Raynaud's phenomenon. In PVD, it helps improve blood flow to the extremities by dilating blood vessels, thereby relieving symptoms such as leg pain, cramping, and intermittent claudication. Raynaud's phenomenon is a condition characterized by episodic narrowing of blood vessels in response to cold or stress, leading to reduced blood flow to the fingers and toes. Ketanserin tartrate hydrate may alleviate symptoms and reduce the frequency and severity of attacks in individuals with Raynaud's phenomenon.

  3. Coronary Artery Disease: Ketanserin tartrate hydrate may have beneficial effects in patients with coronary artery disease (CAD), a condition characterized by the narrowing or blockage of coronary arteries supplying blood to the heart muscle. By dilating coronary arteries, ketanserin tartrate hydrate can improve blood flow to the heart, potentially relieving angina symptoms and reducing the risk of cardiovascular events.

  4. Pulmonary Hypertension: In some cases, ketanserin tartrate hydrate may be used off-label for the treatment of pulmonary hypertension, a condition characterized by elevated blood pressure in the arteries of the lungs. By dilating pulmonary arteries, ketanserin tartrate hydrate may help reduce pulmonary vascular resistance and improve exercise tolerance in patients with pulmonary hypertension.

  5. Adverse Effects: Common side effects of ketanserin tartrate hydrate may include dizziness, lightheadedness, headache, nausea, vomiting, diarrhea, and fatigue. These side effects are usually mild and transient. Rare but potentially serious adverse effects may include hypotension (low blood pressure), bradycardia (slow heart rate), and syncope (fainting). Patients should be monitored for signs of hypotension, especially when initiating or adjusting the dose of ketanserin tartrate hydrate.

  6. Drug Interactions: Ketanserin tartrate hydrate may interact with other medications that affect blood pressure or cardiac function, including beta-blockers, calcium channel blockers, and other antihypertensive agents. Combining ketanserin tartrate hydrate with these medications may increase the risk of hypotension or other adverse effects.

  7. Contraindications: Ketanserin tartrate hydrate is contraindicated in patients with known hypersensitivity to the drug or its components. It should also be used with caution in patients with severe hepatic impairment or renal impairment, as dosage adjustments may be necessary.

  8. Pregnancy and Lactation: The safety of ketanserin tartrate hydrate use during pregnancy and breastfeeding has not been well established. Pregnant or nursing women should consult their healthcare providers before using ketanserin tartrate hydrate to weigh the potential benefits against the risks.

  9. Dosage and Administration: Ketanserin tartrate hydrate is typically administered orally in the form of tablets. The dosage regimen may vary depending on the indication and individual patient factors. It is important to follow the prescribing healthcare provider's instructions and to regularly monitor blood pressure and other relevant parameters during treatment with ketanserin tartrate hydrate.

;

Check for interactions on Supp.AI   |   πŸ“š PubMed Citations   |   βš—οΈ Compensation for antibiotic usage

Data Contradictions β€” Limits of Certainity

Impacted of ketanserin tartrate hydrate,(prescription) On Probiotics

Rank Probiotic Impact
species Lacticaseibacillus paracasei Reduces

Bacteria Impacted by ketanserin tartrate hydrate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

πŸ§™?

Taxonomy Rank Effect Citations Notation
Roseburia genus Decreases 👪 Source Study
Segatella genus Decreases 👪 Source Study
Bilophila genus Decreases 👪 Source Study High Level Cause Brain Fog(Cognitive impairment)
Lacrimispora genus Decreases 👪 Source Study
Thomasclavelia genus Decreases 👪 Source Study
Streptococcus genus Decreases 👪 Source Study
Lacticaseibacillus genus Decreases 👪 Source Study
Mediterraneibacter genus Decreases 👪 Source Study
unclassified Robinsoniella no rank Decreases ⚗️ Source Study
unclassified Fusobacterium no rank Decreases ⚗️ Source Study
unclassified Negativicoccus no rank Decreases ⚗️ Source Study
Eggerthellales order Decreases ⚗️ Source Study
Roseburia hominis species Decreases 📓 Source Study
Segatella copri species Decreases 📓 Source Study Over 70%ile Indicator of mycotoxin present
Bilophila wadsworthia species Decreases 📓 Source Study
Lacrimispora saccharolytica species Decreases 📓 Source Study
Anaerofustis stercorihominis species Decreases ⚗️ Source Study
Asaccharospora irregularis species Decreases ⚗️ Source Study
Thomasclavelia ramosa species Decreases 📓 Source Study
Negativicoccus sp. S5-A15 species Decreases ⚗️ Source Study
Paraprevotella clara species Decreases ⚗️ Source Study
Slackia sp. NATTS species Decreases ⚗️ Source Study
Pseudoflavonifractor capillosus species Decreases ⚗️ Source Study
[Collinsella] massiliensis species Decreases ⚗️ Source Study
Parvibacter caecicola species Decreases ⚗️ Source Study
Streptococcus salivarius species Decreases 📓 Source Study Infectious bacteria
Lacticaseibacillus paracasei species Decreases 📓 Source Study
[Ruminococcus] gnavus species Decreases 📓 Source Study
Streptococcus parasanguinis species Decreases 📓 Source Study
Coriobacterineae suborder Decreases ⚗️ Source Study
Lacticaseibacillus paracasei subsp. paracasei subspecies Decreases 👶 Source Study
Chlamydiae/Verrucomicrobia group superphylum Decreases ⚗️ Source Study

Impact of ketanserin tartrate hydrate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.1 0.1
ADHD 0.2 0.2
Age-Related Macular Degeneration and Glaucoma 0.2 0.2
Allergic Rhinitis (Hay Fever) 0 0
Allergies 0.3 -0.3
Alzheimer's disease 0.1 0.7 -6
Ankylosing spondylitis 0.4 0 0
Anorexia Nervosa 0.2 -0.2
Antiphospholipid syndrome (APS) 0 0.1 0
Asthma 0.2 -0.2
Atherosclerosis 0.2 -0.2
Atrial fibrillation 0 0.4 0
Autism 0.5 0.6 -0.2
Barrett esophagus cancer 0 0
Bipolar Disorder 0.1 0.2 -1
Brain Trauma 0.2 -0.2
Carcinoma 0.1 0.1
Celiac Disease 0 0.1 0
Cerebral Palsy 0 0.2 0
Chronic Fatigue Syndrome 0.2 0 0
Chronic Kidney Disease 0 0.2 0
Chronic Lyme 0.2 -0.2
Chronic Obstructive Pulmonary Disease (COPD) 0.1 0.2 -1
Chronic Urticaria (Hives) 0 0.3 0
Coagulation / Micro clot triggering bacteria 0 0.2 0
Colorectal Cancer 0.3 0.3
Constipation 0.2 -0.2
Coronary artery disease 0 0
COVID-19 0.2 0.8 -3
Crohn's Disease 0.3 0.2 0.5
cystic fibrosis 0.2 -0.2
deep vein thrombosis 0.2 -0.2
Depression 0.6 0.2 2
Dermatomyositis 0 0
Eczema 0 0.1 0
Endometriosis 0 0
Epilepsy 0 0
Fibromyalgia 0.3 0.3 0
Functional constipation / chronic idiopathic constipation 0.5 -0.5
gallstone disease (gsd) 0.2 -0.2
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 0 0
Generalized anxiety disorder 0 0
Glioblastoma 0 0
Graves' disease 0.2 -0.2
Halitosis 0 0
Hashimoto's thyroiditis 0.2 0.1 1
Hidradenitis Suppurativa 0.1 0.1
Histamine Issues,Mast Cell Issue, DAO Insufficiency 0.2 0 0
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 0 0.7 0
IgA nephropathy (IgAN) 0.3 -0.3
Inflammatory Bowel Disease 0.3 0.5 -0.67
Insomnia 0 0.2 0
Intelligence 0.3 -0.3
Irritable Bowel Syndrome 0.2 0.2 0
Liver Cirrhosis 0.3 0.3 0
Long COVID 0.2 0.3 -0.5
Low bone mineral density 0.2 -0.2
ME/CFS with IBS 0 0
ME/CFS without IBS 0.2 0.2
Metabolic Syndrome 0.3 0.7 -1.33
Mood Disorders 0.7 0.2 2.5
multiple chemical sensitivity [MCS] 0.1 0.1
Multiple Sclerosis 0.2 0.5 -1.5
Multiple system atrophy (MSA) 0.4 0.4
Neuropathy (all types) 0 0
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 0.4 0.4
Obesity 0.7 0.1 6
obsessive-compulsive disorder 0 0.3 0
Osteoarthritis 0.2 0.2
pancreatic cancer 0 0
Parkinson's Disease 0.1 0.2 -1
Polycystic ovary syndrome 0.2 -0.2
Psoriasis 0 0.5 0
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 0.7 0.2 2.5
Rosacea 0.2 -0.2
Schizophrenia 0.1 0.2 -1
scoliosis 0.1 -0.1
Sjögren syndrome 0.4 0.4
Sleep Apnea 0.2 -0.2
Small Intestinal Bacterial Overgrowth (SIBO) 0 0
Stress / posttraumatic stress disorder 0.2 0.2 0
Systemic Lupus Erythematosus 0.1 0.2 -1
Tic Disorder 0.3 -0.3
Type 1 Diabetes 0.1 0.2 -1
Type 2 Diabetes 0.3 0.2 0.5
Ulcerative colitis 0 0.6 0
Unhealthy Ageing 0.1 0.2 -1

This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.

Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.

Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β€―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.